Lyra Therapeutics Inc (NAS:LYRA)
$ 0.2675 0.0028 (1.08%) Market Cap: 16.31 Mil Enterprise Value: -33.48 Mil PE Ratio: 0 PB Ratio: 0.21 GF Score: 29/100

Lyra Therapeutics Inc at Stifel Healthcare Conference Transcript

Nov 15, 2022 / 09:10PM GMT
Release Date Price: $3.9 (-2.50%)
Annabel Samimy
Stifel Financial Corp. - Analyst

The Lyra Therapeutics presentation. I'm Annabel Samimy, biopharmaceutical analyst at Stifel -- I almost forgot where I work. And we have Maria Palasis, the CEO of Lyra, who will introduce the company who is solving a matrix for refractory sinusitis. So, why don't you come join us, give the presentation, and we'll go from there.

Maria Palasis
Lyra Therapeutics, Inc. - CEO

Thank you, Annabel. It's a pleasure to be here, and I'm excited to speak about the progress that the company is making. We believe that Lyra is in a really strong position to be able to transform how chronic rhinosinusitis is being treated. It is a disease that just has an enormous un-met need.

We're actually really proud to be one of the few companies that's focused on chronic rhinosinusitis. It's a population in the US of about 14 million patients that have this disease. And unfortunately, there's not a drug that's approved to treat these patients. It's a global problem -- not just in the US, but throughout the world, with millions

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot